Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).
Type:
Grant
Filed:
September 20, 2010
Date of Patent:
June 24, 2014
Assignee:
One Way Liver Genomics, S.L.
Inventors:
Jonathan Barr, Azucena Castro Espido, Jose Maria Mato De La Paz, Maria Luz Martinez Chantar
Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).
Type:
Grant
Filed:
August 11, 2009
Date of Patent:
October 22, 2013
Assignee:
One Way Liver Genomics, S.L.
Inventors:
Jonathan Barr, Azucena Castro Espido, Jose Maria Mato De La Paz, Maria Luz Martinez Chantar
Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).
Type:
Application
Filed:
September 20, 2010
Publication date:
July 26, 2012
Applicant:
One Way Liver Genomics, S.L.
Inventors:
Jonathan Barr, Azucena Castro Espido, Jose Maria Mato De La Paz, Maria Luz Martinez Chantar
Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).
Type:
Application
Filed:
August 11, 2009
Publication date:
July 28, 2011
Applicant:
ONE WAY LIVER GENOMICS, S.L.
Inventors:
Jonathan Barr, Azucena Castro Espido, Jose Maria Mato De La Paz, Maria Luz Martinez Chantar
Abstract: Phosphorylated Sp1 can be used as a marker for in vitro diagnosis of non-alcoholic steatohepatitis (NASH) as well as a therapeutical target of said condition.
Abstract: The invention relates to a method of diagnosing non-alcoholic steatohepatitis (NASH) using molecular markers. The inventive method consists in detecting and quantifying, in vitro in a hepatic tissue sample, the levels of a protein which can be used as a NASH molecular marker and which is selected from apolipoprotein A1, sub-unit ? of the mitochondrial ATPase, leukotriene A4 hydrolase, keratin 18, guanidine acetate N-methyltransferase, superoxide dismutase, albumin, antioxidant protein 2 (isoform 1), prohibitin 1, methionine adenosyl transferase, long-chain acyl CoA dehydrogenase, selenium binding protein, antioxidant protein 2 (isoform 2), and combinations of same. The invention further consists in comparing the results obtained with the normal values of said proteins in healthy hepatic tissue. Said method can be used to diagnose NASH and/or to assess a patient's potential risk of developing NASH.
Type:
Grant
Filed:
December 16, 2003
Date of Patent:
January 1, 2008
Assignee:
One Way Liver Genomic, S.L.
Inventors:
José María Mato De La Paz, Fernando Corrales Izquierdo, Enrique Santa María Martínez
Abstract: A set of genes that are expressed differentially in normal and NASH-predisposed liver, thus constituting the genomic signature of NASH, is provided. The set of genes can be used to discriminate between normal and NASH-predisposed liver tissues. Accordingly, diagnostic assays for classification of pathological grades, prediction of the pathology outcome, selecting and monitoring treatment regimens and monitoring disease progression/regression also are provided.